Drug Patents owned by Takeda Pharms Usa

1. Drug name - ACTOPLUS MET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101660 TAKEDA PHARMS USA Solid preparation
Jan, 2027

(4 years from now)

US9320714 TAKEDA PHARMS USA Tablet
Feb, 2029

(6 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 August, 2005

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
500MG;EQ 15MG BASE TABLET;ORAL Prescription
850MG;EQ 15MG BASE TABLET;ORAL Prescription

2. Drug name - ACTOPLUS MET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9060941 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(9 months from now)

US8470368 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(9 months from now)

US8668931 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(9 months from now)

US7959946 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(3 years from now)

US7785627 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(3 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 12 May, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM;EQ 15MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
1GM;EQ 30MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

3. Drug name - ALUNBRIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Apr, 2031

(8 years from now)

US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077 TAKEDA PHARMS USA Phosphorus derivatives as kinase inhibitors
May, 2029

(6 years from now)

US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers
Apr, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
Orphan Drug Exclusivity (ODE) May 22, 2027
New Indication (I) May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription
180MG TABLET;ORAL Prescription

4. Drug name - COLCRYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8415396 TAKEDA PHARMS USA Colchine compositions and methods
Oct, 2028

(5 years from now)

US8093297 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Oct, 2028

(5 years from now)

US7981938 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(5 years from now)

US7964648 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Oct, 2028

(5 years from now)

US8093296 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(5 years from now)

US8097655 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(5 years from now)

US7964647 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(5 years from now)

US8093298 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(5 years from now)

US8415395 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(5 years from now)

US7935731 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Dec, 2028

(5 years from now)

US7619004 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Dec, 2028

(5 years from now)

US7601758 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
Feb, 2029

(6 years from now)

US7915269 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(6 years from now)

US7820681 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(6 years from now)

US8440722 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(6 years from now)

US7906519 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(6 years from now)

US8440721 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(6 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 29 July, 2009

Treatment: Method of treating gout flares; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; A method for treatment of gout flares during prophylaxis; Method of using colchicine for the prophylaxis of gout flares; Method of administering colchicine to familial mediterranean fever patients

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.6MG TABLET;ORAL Prescription

5. Drug name - DEXILANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(a month from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(7 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(10 months from now)

US8722084 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(10 months from now)

US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 4 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 4 months from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(3 years from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(3 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(3 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(3 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation
Aug, 2026

(3 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Sep, 2026

(3 years from now)

US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Feb, 2027

(4 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Mar, 2027

(4 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(5 years from now)

US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Mar, 2030

(7 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Sep, 2030

(7 years from now)

US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Mar, 2032

(9 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); To maintain healing of ee and relief of heartburn; For healing of all grades of erosive esophagitis (ee); Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months; Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE, DELAYED RELEASE;ORAL Prescription
60MG CAPSULE, DELAYED RELEASE;ORAL Prescription

6. Drug name - DEXILANT SOLUTAB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(a month from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(7 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(10 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 4 months from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(3 years from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(3 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(3 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(3 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(5 years from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules
Jul, 2028

(5 years from now)

US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation
Mar, 2029

(6 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Discontinued

7. Drug name - DUETACT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700128 TAKEDA PHARMS USA Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
Jan, 2027

(4 years from now)

US8071130 TAKEDA PHARMS USA Solid preparation
Jun, 2028

(5 years from now)

Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 July, 2006

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG;30MG TABLET;ORAL Prescription
4MG;30MG TABLET;ORAL Prescription

8. Drug name - EXKIVITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(12 years from now)

US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 15, 2026
Orphan Drug Exclusivity (ODE) Sep 15, 2028

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

Market Authorisation Date: 15 September, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription

9. Drug name - FOSRENOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7465465 TAKEDA PHARMS USA Pharmaceutical formulation comprising lanthanum compounds
Aug, 2024

(1 year, 8 months from now)

US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions
Aug, 2024

(1 year, 8 months from now)

US9023397 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(7 years from now)

US8980327 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(7 years from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 26 October, 2004

Treatment: Reduction of serum phosphate in patients with end stage renal disease

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE TABLET, CHEWABLE;ORAL Prescription
EQ 250MG BASE TABLET, CHEWABLE;ORAL Discontinued
EQ 500MG BASE TABLET, CHEWABLE;ORAL Prescription
EQ 750MG BASE TABLET, CHEWABLE;ORAL Prescription

10. Drug name - ICLUSIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114874 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Jan, 2027

(4 years from now)

US9493470 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(11 years from now)

US11192897 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(11 years from now)

US11384086 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9029533 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors
Dec, 2026

(4 years from now)

US11192895 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 18, 2023

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 14 December, 2012

Treatment: A method of treating chronic myelogenous leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; A method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; A method for the treatment of leukemias; A method for treating acute lymphoblastic leukemia; A method for treating chronic myeloid leukemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 45MG BASE TABLET;ORAL Prescription

11. Drug name - INTUNIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6811794 TAKEDA PHARMS USA Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Jul, 2022

(5 months ago)

US6811794

(Pediatric)

TAKEDA PHARMS USA Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Jan, 2023

(25 days from now)

Drugs and Companies using GUANFACINE HYDROCHLORIDE ingredient

Market Authorisation Date: 02 September, 2009

Treatment: Treatment of attention-deficit hyperactivity disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 2MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 3MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 4MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

12. Drug name - KAZANO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2025

(2 years from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

US8900638 TAKEDA PHARMS USA Solid preparation comprising alogliptin and metformin hydrochloride
May, 2029

(6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;1GM TABLET;ORAL Prescription
EQ 12.5MG BASE;500MG TABLET;ORAL Prescription

13. Drug name - MYDAYIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6913768 TAKEDA PHARMS USA Sustained release delivery of amphetamine salts
May, 2023

(5 months from now)

US9173857 TAKEDA PHARMS USA Controlled dose drug delivery system
May, 2026

(3 years from now)

US8846100 TAKEDA PHARMS USA Controlled dose drug delivery system
Aug, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
M Sep 13, 2022
Pediatric Exclusivity (PED) Mar 13, 2023

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 20 June, 2017

Treatment: Treatment of attention deficit hyperactivity disorder

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
3.125MG;3.125MG;3.125MG;3.125MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
6.25MG;6.25MG;6.25MG;6.25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
9.375MG;9.375MG;9.375MG;9.375MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
12.5MG;12.5MG;12.5MG;12.5MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

14. Drug name - NESINA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Dec, 2025

(2 years from now)

US8697125 TAKEDA PHARMS USA Tablet preparation without causing a tableting trouble
Jun, 2029

(6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE ingredient

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 6.25MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

15. Drug name - NINLARO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546608 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(1 year, 8 months from now)

US8530694 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US8003819 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US7687662 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US8859504 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof
Jun, 2029

(6 years from now)

US7442830 TAKEDA PHARMS USA Proteasome inhibitors
Nov, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233115 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(1 year, 8 months from now)

US8871745 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US9175017 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof
Jun, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 20, 2022

Drugs and Companies using IXAZOMIB CITRATE ingredient

Market Authorisation Date: 20 November, 2015

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.3MG BASE CAPSULE;ORAL Prescription
EQ 3MG BASE CAPSULE;ORAL Prescription
EQ 4MG BASE CAPSULE;ORAL Prescription

16. Drug name - OMONTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 5 months from now)

US7528104 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 5 months from now)

US7919118 TAKEDA PHARMS USA Spacer moiety for poly (ethylene glycol) modified peptide based compounds
May, 2024

(1 year, 5 months from now)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7550433 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(3 years from now)

US7919461 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(3 years from now)

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Market Authorisation Date: 27 March, 2012

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 20MG BASE/2ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued

17. Drug name - OSENI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

US8637079 TAKEDA PHARMS USA Solid preparation comprising alogliptin and pioglitazone
Jun, 2029

(6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;EQ 15MG BASE TABLET;ORAL Discontinued
EQ 12.5MG BASE;EQ 30MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE;EQ 45MG BASE TABLET;ORAL Discontinued
EQ 25MG BASE;EQ 15MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 30MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 45MG BASE TABLET;ORAL Prescription

18. Drug name - TRINTELLIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7144884 TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Jun, 2026

(3 years from now)

US8722684 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476279 TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Oct, 2022

(2 months ago)

US8969355 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US11458134 TAKEDA PHARMS USA 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9861630 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9125908 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9125909 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9125910 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9227946 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9278096 TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
M Jan 22, 2024

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

Market Authorisation Date: 30 September, 2013

Treatment: Method of treating an affective disorder such as depression; Method of treating depression or major depressive disorder; Use of trintellix for the treatment of major depressive disorder (mdd) in adults; Use in the treatment of major depressive disorder to improve processing speed, an aspect of cognitive function; Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Discontinued
EQ 20MG BASE TABLET;ORAL Prescription

19. Drug name - ULORIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361676 TAKEDA PHARMS USA Solid preparation containing single crystal form
Mar, 2024

(1 year, 2 months from now)

US8372872 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat
Sep, 2031

(8 years from now)

US9107912 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat
Sep, 2031

(8 years from now)

Drugs and Companies using FEBUXOSTAT ingredient

Market Authorisation Date: 13 February, 2009

Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription

20. Drug name - VELCADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6713446 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(10 months ago)

US6958319 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(10 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6958319

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(4 months ago)

US6713446

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(4 months ago)

Exclusivity Exclusivity Expiration
Pediatric Exclusivity (PED) Apr 8, 2022

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 13 May, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
3.5MG/VIAL INJECTABLE;INTRAVENOUS, SUBCUTANEOUS Prescription

21. Drug name - VYVANSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7659253 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7662787 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(2 months from now)

US7655630 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7671031 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7659254 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7105486 TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Feb, 2023

(2 months from now)

US7662788 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7674774 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7678771 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7723305 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7713936 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7700561 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7687466 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7223735 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(2 months from now)

US7718619 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7678770 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7687467 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7671030 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(2 months from now)

US7662788

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7718619

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7223735

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(8 months from now)

US7655630

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7659253

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7662787

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(8 months from now)

US7659254

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7671030

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7671031

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7674774

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7678770

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7678771

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7687466

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7687467

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7713936

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7700561

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

US7105486

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Aug, 2023

(8 months from now)

US7723305

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(8 months from now)

Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient

Market Authorisation Date: 28 January, 2017

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disorder (adhd) in adults; Indicated for the treatment of attention-deficit/hyperactivity disorder (adhd)

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, CHEWABLE;ORAL Prescription
20MG TABLET, CHEWABLE;ORAL Prescription
30MG TABLET, CHEWABLE;ORAL Prescription
40MG TABLET, CHEWABLE;ORAL Prescription
50MG TABLET, CHEWABLE;ORAL Prescription
60MG TABLET, CHEWABLE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in